Premium
Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders
Author(s) -
Brown Jennifer R.,
Neuberg Donna,
Phillips Kimberly,
Reynolds Hazel,
Silverstein Jason,
Clark Jennifer C.,
Ash Megan,
Thompson Christina,
Fisher David C.,
Jacobsen Eric,
LaCasce Ann S.,
Freedman Arnold S.
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07355.x
Subject(s) - medicine , proband , lymphoproliferative disorders , lymphoma , malignancy , chronic lymphocytic leukemia , first degree relatives , family history , population , cancer , oncology , pediatrics , leukemia , genetics , environmental health , gene , mutation , biology
Summary Increasing evidence points to a heritable contribution in the development of lymphoma. The goal of this study was to determine the rate of familial lymphoproliferative malignancy among consecutive lymphoma patients presenting to a tertiary care center and to enrol families with multiple affected first‐degree relatives on a data and tissue collection study. Beginning in 2004 all new patients presenting to the Dana‐Farber Cancer Institute with non‐Hodgkin (NHL) or Hodgkin lymphoma (HL) or chronic lymphocytic leukaemia (CLL) were asked to complete a one‐page self‐administered family history questionnaire. 55·4% of 1948 evaluable patients reported a first‐degree relative with a malignancy, with the highest rate among CLL probands. Lymphoid malignancies were particularly common, with 9·4% of all probands reporting a first‐degree relative with a related lymphoproliferative disorder (LPD). This frequency was again highest for CLL, at 13·3% of CLL probands, compared to 8·8% of NHL probands and 5·9% of HL probands ( P = 0·002). The prevalence of CLL was significantly increased in parents of CLL probands ( P < 0·05), and a greater risk of NHL was seen in fathers of NHL probands than in mothers ( P = 0·026). We conclude that familial aggregation of LPDs is common among newly diagnosed patients, varies significantly by diagnosis and contributes meaningfully to the population disease burden.